Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 751 to 765 of 878 results for score

  1. Alpha-Stim AID for anxiety disorders (HTG570)

    Evidence-based recommendations on Alpha-Stim AID for managing anxiety disorders.

  2. Lung texture analysis for measuring interstitial lung diseases (MIB272)

    NICE has developed a medtech innovation briefing (MIB) on lung texture analysis for measuring interstitial lung diseases .

  3. XprESS multi sinus dilation system for treating chronic sinusitis (HTG424)

    Evidence-based recommendations on the XprESS multi-sinus dilation system for treating chronic sinusitis after medical treatment has failed.

  4. Tegaderm CHG securement dressing for vascular access sites in critically ill adults (HTG379)

    Evidence-based recommendations on Tegaderm CHG securement dressing for vascular access sites in critically ill adults.

  5. HumiGard for preventing inadvertent perioperative hypothermia (HTG428)

    Evidence-based recommendations on HumiGard for preventing inadvertent perioperative hypothermia.

  6. Depression in adults: treatment and management (NG222)

    This guideline covers identifying, treating and managing depression in people aged 18 and over. It recommends treatments for first episodes of depression and further-line treatments, and provides advice on preventing relapse, and managing chronic depression, psychotic depression and depression with a coexisting diagnosis of personality disorder.

  7. Herbal medicines:- Are Chinese and non-Chinese herbal medicines safe and effective as first-line therapy in the treatment of [Irritable bowel syndrome] (IBS), and which is the most effective and safe option?

    primary outcome should be global improvement in IBS symptoms, with symptom scores recorded using a validated scale. Health-related...

  8. Cardiovascular disease prevention: primary prevention with lipid lowering therapies (IND229)

    This indicator covers the percentage of patients with a cardiovascular disease risk assessment score of 10% or more who are currently treated with a lipid-lowering therapy. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM211

  9. Predictors of acute physical risk:- What clinical and biochemical markers are the best predictors of acute physical risk for people with eating disorders?

    Validated tools (such as Acute Physiology and Chronic Health Evaluation [APACHE] scores) are central to risk prediction in other areas...

  10. Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis (TA959)

    Evidence-based recommendations on daratumumab (Darzalex) for newly diagnosed systemic amyloid light-chain amyloidosis in adults.

  11. Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable (TA917)

    Evidence-based recommendations on daratumumab (Darzalex) with lenalidomide and dexamethasone for untreated multiple myeloma in adults, when a stem cell transplant is unsuitable.

  12. Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency (TA709)

    Evidence-based recommendations on pembrolizumab (Keytruda) for treating metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency in adults.

  13. Safe midwifery staffing for maternity settings (NG4)

    This guideline covers safe midwifery staffing in all maternity settings, including at home, in the community, in day assessment units, in obstetric units, and in units led by midwives (both alongside hospitals and free-standing). It aims to improve maternity care by giving advice on monitoring staffing levels and actions to take if there are not enough midwives to meet the needs of women and babies in the service.

  14. Servo-n with Neurally Adjusted Ventilatory Assist (NAVA) for babies and children (MIB163)

    NICE has developed a medtech innovation briefing (MIB) on Serve-n with Neurally Adjusted Ventilatory Assist (NAVA) for babies and children .

  15. Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer (TA1037)

    Evidence-based recommendations on pembrolizumab (Keytruda) for the adjuvant treatment of resected non-small-cell lung cancer in adults.